For Multiple Myeloma Patients at High Risk for Infection, Chemotherapy without High-dose Dexamethasone Can Help

Web Exclusives

Avoiding intermittent highdose dexamethasone (HD) when administering the vincristine/ doxorubicin/dexamethasone (VAD) regimen can reduce the risk for bacterial infection in patients with multiple myeloma (MM), suggest the results of a Japanese study published in the January issue of the International Journal of Hematology.

Although the VAD-HD combination is often used as primary therapy in MM patients who are candidates for high-dose therapy or present with renal failure, the high doses of a glucocorticoid can suppress their immune system, placing them at high risk for bacterial infections. To test if the VAD regimen could be equally effective without the HD component (and thus reduce patients’ risk for infection), the researchers retrospectively evaluated MM patients receiving VAD with or without HD. In the VAD group (n = 37), patients were treated in two to four 21-day cycles on days 1 to 4. In the VAD-HD group (n = 40), patients underwent the same dosing schedule plus intravenous dexamethasone on days 9 to 12 and 17 to 20 of each 28-day cycle.

The researchers identified 48 infection episodes, including pneumonia, urinary tract infections, and staphylococcus infections, in 39 patients. Of these, 32 episodes in 26 patients were grade 3. Analyzing each patient, they found VAD-HD to be associated with risk of all-grade and severe bacterial infection; ISS stage ≥2 independently correlated with severe bacterial infection.

No statistically significant differences in overall response rates were found; 62.9% in the VAD group versus 50% in the VAD-HD gro

Related Items
Hallmark Health Hematology and Oncology Center
Dawn Lagrosa
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Cancer Center Profile
Children’s Memorial Center for Cancer and Blood Diseases
Dawn Lagrosa
TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in Cancer Center Profile
Porter Cancer Care Center
Dawn Lagrosa
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Cancer Center Profile
13 Comorbid Conditions Decrease Survival, Increase Mortality in Elderly Breast Cancer Patients
Dawn Lagrosa
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Breast Cancer
New Oncology Pharmacy Provides “Cleanest Possible Product”
Dawn Lagrosa
TOP - June 2011, Vol 4, No 4 published on June 27, 2011 in Cancer Center Profile
St. Joseph Mercy Cancer Care Center
Dawn Lagrosa
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Cancer Center Profile
Voluntary Recall of Irinotecan Announced
Dawn Lagrosa
Web Exclusives published on April 28, 2011 in FDA Updates
Waukesha Memorial Hospital’s Regional Cancer Center
Dawn Lagrosa
TOP - February 2011, Vol 4, No 1 published on February 17, 2011 in Cancer Center Profile
Geisinger Medical Center’s Cancer Institute Joins the NCCCP
Dawn Lagrosa
TOP - December 2010, Vol 3, No 8 published on November 30, 2010
Western Michigan Cancer Center: A Cancer Center Innovator
Dawn Lagrosa
TOP - February 2010 Vol 3, No 1 published on June 10, 2010
Last modified: July 22, 2021